NCT05184842 Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML Status RECRUITING Phase PHASE2
NCT05183035 Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) Status RECRUITING Phase PHASE3
NCT05182385 Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT05177731 Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT05168202 A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes Status TERMINATED Phase PHASE1
NCT05157971 Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia Status RECRUITING Phase PHASE1
NCT05155709 A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. Status COMPLETED Phase PHASE1
NCT05144243 Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China Status ACTIVE_NOT_RECRUITING Phase PHASE4
NCT05107856 PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies Status TERMINATED Phase PHASE1
NCT05105841 Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Status COMPLETED Phase PHASE2
NCT05091424 A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia Status RECRUITING Phase PHASE1
NCT05079230 Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia Status TERMINATED Phase PHASE3
NCT05074355 Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms Status RECRUITING Phase PHASE2
NCT05057494 A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT05054465 A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALL Status NOT_YET_RECRUITING Phase PHASE1/PHASE2
NCT05053659 Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT05053425 Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML Status UNKNOWN Phase NA
NCT05010772 Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission Status RECRUITING Phase PHASE1